LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301)

Mitry, Emmanuel; Dahan, Laétitia; Ychou, M.; Arthaud, J.; Gasmi, Mohamed; Raoul, J.L.; Mariette, C.; Phelip, Jean Marc; Bedenne, Laurent; Seitz, Julia

doi:10.1200/jco.2008.26.15_suppl.4513

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have been very few attempts to address the role of alternative cytotoxic agents (which may represent better platforms for the addition of targeted therapies) other than gemcitabine in the first-line setting. The FFCD group randomized 202 patients with advanced, untreated pancreatic cancer to gemcitabine or 5-FU plus cisplatin [ 44 ]. Patients received therapy until progression, after which they could cross to the opposite arm.…”

Section: Pancreatic Cancermentioning

confidence: 99%

Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

Javle

Hsueh

2009

J Hematol Oncol

View full text Add to dashboard Cite

We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment. The results of double biologics (bevacizumab and anti-EGFR antibody) plus chemotherapy as first-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen. Microsatellite Instability has again been confirmed to be an important predictor in patients with stage II colon cancer receiving adjuvant treatment.Adjuvant gemcitabine therapy for pancreatic cancer was investigated by the CONKO-001 study; this resulted in superior survival as compared with observation and can be regarded as an acceptable option, without the addition of radiotherapy. The addition of bevacizumab to gemcitabine and erlotinib was not supior to gemcitabine and erlotinib for advanced disease. Second-line therapy for advanced pancreatic cancer with 5-fluorouracil and oxaliplatin resulted in a survival benefit. Irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when combined with radiotherapy for esophageal cancer. The novel fluoropyrimidine S1 appears to be active in gastric cancer, as a single agent or as combination therapy. Adjuvant intraperitoneal mitomycin-C may decrease the incidence of peritoneal recurrence of gastric cancer. Sorafenib is an effective agent in Asian patients with hepatocellular carcinoma secondary to hepatitis B; its utility in child's B cirrhosis remains to be proven. Sunitinib is also an active agent in hepatocellular carcinoma, and may represent an alterative to sorafenib for advanced disease. These and other important presentations from the 2008 ASCO annual meeting are discussed in this article.

show abstract

Section: Pancreatic Cancermentioning

confidence: 99%

Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

Javle

Hsueh

2009

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…Wie viele Patienten von dieser Sequenz profitieren können, bleibt unklar, aber sie scheint besser zu sein als die umgekehrte Reihenfolge. Zuerst 5-FU/FS/Cisplatin, dann Gemcitabine wurde von der französischen FFCD in einer randomisierten Studie an 202 Patienten untersucht [35] und ist im direkten Vergleich zwar nicht signifikant unterlegen, aber doch tendenziell weniger wirksam (PFS 3,8 vs. 4,7 und Gesamtüberleben 6,6 vs. 8,0) und toxischer als Gemcitabine gefolgt von der 5-FU-basierten Kombination. Nach wie vor ist unklar, ob Patienten mit lokal fortgeschrittenen Tumoren zusätzlich bestrahlt werden sollten.…”

Section: Palliative Therapie Des Pankreaskarzinomsunclassified

“…Nach wie vor ist unklar, ob Patienten mit lokal fortgeschrittenen Tumoren zusätzlich bestrahlt werden sollten. Die ECOG-E4201-Studie, die Gemcitabine (600 mg/m 2 ) plus Strahlentherapie (50,4 Gy) mit Gemcitabine in Standarddosierung vergleicht, war für 316 inoperable, lokal fortgeschrittene Patienten geplant und wurde mangels Rekrutierung nach Einschluss von 71 Patienten beendet [35]. Trotzdem zeigt sie eine signifikante Verlängerung des medianen Überlebens von 9,2 auf 11,0 Monate (p = 0,044), allerdings ohne Unterschied beim progressionsfreien Überleben.…”

Section: Palliative Therapie Des Pankreaskarzinomsunclassified

Gastrointestinale Onkologie – Therapieupdate 2008 / 2009

Ebert¹,

Auernhammer²,

Caca³

et al. 2009

Z Gastroenterol

View full text Add to dashboard Cite

As a consequence of recent studies the treatment of gastrointestinal cancers has become challenging and is undergoing constant changes on the basis of the results of new trials. The steering committee of the working group on gastrointestinal cancers of the Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten has decided to summarise and present recent updates of the current treatment guidelines and recommendations for the most relevant gastrointestinal malignancies. In this review we have included recent findings from large trials on esophageal, gastric, pancreatic, cholangiocellular and liver cancers, as well as colorectal cancers, neuroendocrine tumours and lymphomas. This includes an update on the combination with novel targeted agents and the introduction of potential predictive biomarkers in the selection of the appropriate treatment strategy.

show abstract

Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117 patients

Bachet

Mitry

Lièvre

et al. 2009

Gastroentérologie Clinique et Biologique

View full text Add to dashboard Cite

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301)

Cited by 5 publications

References 0 publications

Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

Gastrointestinale Onkologie – Therapieupdate 2008 / 2009

Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117 patients

Contact Info

Product

Resources

About